This $241,823 federal Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) supports the development of an implantable engineered tissue with optogenetically engineered human beta-cells. The project aims to address challenges in creating vascularized tissues with light-activatable cells to improve treatment for diabetes. Key activities include designing a gelatin-based engineered tissue with oxygen-generating microparticles and optogenetically engineered beta-cells, establishing conditions for angiogenesis within the tissue, and evaluating the functionality of the engineered tissue in a mouse model of diabetes. The project period runs from September 1, 2023 to August 31, 2026.
Generated 6/18/24, 11:52 AM